Efficacy and safety of once-weekly GLP-1 receptor agonist albiglutide (HARMONY 2): 52 week primary endpoint results from a randomised, placebo-controlled trial in patients with type 2 diabetes mellitus inadequately controlled with diet and exercise (Q36441684)
Jump to navigation
Jump to search
scientific article published on 17 November 2015
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Efficacy and safety of once-weekly GLP-1 receptor agonist albiglutide (HARMONY 2): 52 week primary endpoint results from a randomised, placebo-controlled trial in patients with type 2 diabetes mellitus inadequately controlled with diet and exercise |
scientific article published on 17 November 2015 |
Statements
1 reference
Efficacy and safety of once-weekly GLP-1 receptor agonist albiglutide (HARMONY 2): 52 week primary endpoint results from a randomised, placebo-controlled trial in patients with type 2 diabetes mellitus inadequately controlled with diet and exercise (English)
1 reference
Michael A Nauck
1 reference
Murray W Stewart
1 reference
Christopher Perkins
1 reference
Angela Jones-Leone
1 reference
Fred Yang
1 reference
Caroline Perry
1 reference
Rickey R Reinhardt
1 reference
Marc Rendell
1 reference
17 November 2015
1 reference
1 reference
Identifiers
1 reference